RLMD on Nasdaq

RELMADA THERAPEUTICS, INC.

American pharmaceutical preparations company based in New York.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

TickerRLMD on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersNew York, United States
Incorporated inNV²
Business address2222 Ponce De Leon Blvd. 3Rd Floor, Coral Gables, Fl 33134²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income³⁴⁵⁶⁷⁸-$59.1M in 2025+291% since 2019

Net income³⁴⁵⁶⁷⁸-$57.4M in 2025+282% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Research and development	$26.9M	$46.2M
General and administrative	$32.2M	$37.7M
Total operating expenses	$59.1M	$83.9M
Loss from operations	-$59.1M	-$83.9M
Interest/investment income, net	$1.4M	$3.5M
Realized (loss) gain on short-term investments	-$79.2K	$374.9K
Unrealized gain on short-term investments	$398.3K	$6.7K
Total other income (expenses), net	$1.7M	$3.9M
Net loss	-$57.4M	-$80.0M
Loss per common share basic (in Dollars per share)	-$1.45	-$2.65
Loss per common share diluted (in Dollars per share)	-$1.45	-$2.65
Weighted average number of common shares outstanding basic (in Shares)	39.5M shares	30.2M shares
Weighted average number of common shares outstanding diluted (in Shares)	39.5M shares	30.2M shares

Total assets³⁴⁵⁶⁷⁸$94.0M in 2025−20% since 2019

Total liabilities³⁴⁵⁶⁷⁸$7.5M in 2025+414% since 2019

Shareholders’ equity⁴⁵⁶⁷⁸$86.5M in 2025−25% since 2019

Cash³⁵⁶⁷⁸$3.5M in 2025−90% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁸

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$3.5M	$3.9M
Short-term investments	$89.5M	$41.1M
Prepaid expenses	$977.7K	$886.5K
Total current assets	$94.0M	$45.8M
Other assets	$19.5K	$22.0K
Total assets	$94.0M	$45.8M
Accounts payable	$1.6M	$4.1M
Accrued expenses	$4.9M	$6.2M
Total current liabilities	$6.4M	$10.3M
Stock appreciation rights	$1.1M	$4.5K
Total liabilities	$7.5M	$10.3M
Common stock, $0.001 par value, 150,000,000 shares authorized, 73,333,622 and 30,174,202 shares issued and outstanding, respectively	$73.3K	$30.2K
Additional paid-in capital	$784.7M	$676.4M
Accumulated deficit	-$698.3M	-$640.9M
Total stockholders equity	$86.5M	$35.5M	$85.4M
Total liabilities and stockholders equity	$94.0M	$45.8M
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in Shares)	200.0M shares	200.0M shares
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized (in Shares)	150.0M shares	150.0M shares
Common stock, shares issued (in Shares)	73.3M shares	30.2M shares
Common stock, shares outstanding (in Shares)	73.3M shares	30.2M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$3.5M	$3.9M
Short-term investments	$89.5M	$41.1M
Prepaid expenses	$977.7K	$886.5K
Total current assets	$94.0M	$45.8M
Other assets	$19.5K	$22.0K
Total assets	$94.0M	$45.8M
Accounts payable	$1.6M	$4.1M
Accrued expenses	$4.9M	$6.2M
Total current liabilities	$6.4M	$10.3M
Stock appreciation rights	$1.1M	$4.5K
Total liabilities	$7.5M	$10.3M
Common stock, $0.001 par value, 150,000,000 shares authorized, 73,333,622 and 30,174,202 shares issued and outstanding, respectively	$73.3K	$30.2K
Additional paid-in capital	$784.7M	$676.4M
Accumulated deficit	-$698.3M	-$640.9M
Total stockholders equity	$86.5M	$35.5M	$85.4M
Total liabilities and stockholders equity	$94.0M	$45.8M
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in Shares)	200.0M shares	200.0M shares
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized (in Shares)	150.0M shares	150.0M shares
Common stock, shares issued (in Shares)	73.3M shares	30.2M shares
Common stock, shares outstanding (in Shares)	73.3M shares	30.2M shares

Cash from operations³⁴⁵⁶⁷⁸-$45.8M in 2025+279% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Net loss	-$57.4M	-$80.0M
Stock-based compensation	$13.9M	$30.2M
Stock appreciation rights compensation	$1.1M	$4.5K
Issuance of restricted common stock	$905.2K
Realized (gain) loss on short-term investments	$79.2K	-$374.9K
Unrealized gain on short-term investments	-$398.3K	-$6.7K
Prepaid expenses and other assets	-$88.8K	$319.7K
Accounts payable	-$2.6M	$624.6K
Accrued expenses	-$1.3M	-$2.5M
Net cash used in operating activities	-$45.8M	-$51.8M
Purchase of short-term investments	-$83.8M	-$12.1M
Sale of short-term investments	$35.7M	$63.6M
Net cash (used in)/provided by investing activities	-$48.1M	$51.6M
Proceeds from issuance of common stock, net	$93.6M
Payment of ATM fees	-$73.0K	-$287.1K
Proceeds from options exercised for common stock		$246.7K
Net cash provided by/(used in) financing activities	$93.6M	-$40.3K
Net decrease in cash and cash equivalents	-$360.5K	-$234.5K

Compare RELMADA THERAPEUTICS, INC. with another company

Leadership

Who has led RELMADA THERAPEUTICS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

Sergio Traversa2015–now

President

Eliseo Oreste Salinas2015

Chief financial officer

Chief operating officer

20202025

Chief executive officerSergio Traversa Jan 16, 2015 to now¹¹
PresidentEliseo Oreste Salinas Jan 16, 2015 to Mar 5, 2015¹²
Chief financial officerMaged Shenouda Jan 11, 2021 to now¹³
Chief financial officerChuck Ence Jul 30, 2019 to Dec 23, 2019¹⁴
Chief financial officerDouglas Beck Jan 16, 2015 to Mar 5, 2015¹⁵
Chief operating officerPaul Edward Kelly May 20, 2025 to Nov 6, 2025¹⁶
Chief operating officerChuck Ence Nov 6, 2025 to now¹⁷

Board members and other officers (13)

Chief Medical OfficerCedric O'Gorman Jan 13, 2023 to May 24, 2023¹⁸
Chief Compliance OfficerChuck Ence Jan 11, 2021 to now¹⁹
Chief Medical OfficerOttavio Vitolo V. Apr 3, 2018 to Dec 23, 2019²⁰
Chief Business OfficerLisa Nolan Dec 17, 2015 to Dec 17, 2015²¹
Board memberFabiana Fedeli Jan 13, 2023 to now²²
Board memberJohn Glasspool Jan 6, 2020 to now²³
Board memberNabil Yazgi Jan 16, 2015 to Jan 16, 2015²⁴
Board memberSandesh Seth Jan 16, 2015 to Dec 17, 2015²⁵
Board memberSergio Traversa Jan 16, 2015 to now¹¹
Board memberShreeram Agharkar Jan 16, 2015 to Jan 5, 2016²⁶
Board memberCharles J. Casamento Jul 16, 2015 to now²⁷
Board memberMaged Shenouda Nov 16, 2015 to Dec 23, 2019²⁸
Board memberPaul Edward Kelly Nov 16, 2015 to now²⁹

Former names

CAMP NINE, INC.Nov 13, 2012 to Jul 14, 2014²

Timeline

Jan 16, 2015New chief executive Sergio Traversa becomes CEO¹¹

Filings

252 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 70 major events, 92 insider forms, 38 large holders, 32 other. The latest 20:

Sep 11, 20264 OWNERSHIP DOCUMENT EDGAR
Sep 11, 20264 EDGAR
Sep 8, 20268-K CURRENT REPORT EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 6, 20268-K CURRENT REPORT EDGAR
Aug 6, 202610-Q QUARTERLY REPORT EDGAR
Jul 29, 2026SCHEDULE 13G EDGAR
Jul 28, 20268-K CURRENT REPORT EDGAR
Jun 22, 2026SCHEDULE 13G EDGAR
Jun 18, 2026S-8 REGISTRATION STATEMENT EDGAR
Jun 9, 2026SCHEDULE 13G EDGAR
May 28, 20268-K CURRENT REPORT EDGAR
May 13, 2026S-3ASR REGISTRATION STATEMENT EDGAR
May 13, 2026SCHEDULE 13G/A EDGAR
May 12, 20268-K CURRENT REPORT EDGAR
May 12, 202610-Q QUARTERLY REPORT EDGAR
May 4, 2026SCHEDULE 13G EDGAR
Apr 17, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
Apr 17, 2026DEF 14A PROXY STATEMENT EDGAR
Apr 9, 2026EFFECT EDGAR

The 252 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 38 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Jupiter Topco LLC	11,164,803	$77.3M	0.0%	New
BlackRock, Inc.	7,426,780	$51.4M	0.0%	+6,137,230
Squadron Capital Management LLC	7,350,000	$50.9M	17.4%	−1,124,571
Venrock Adviser, LLC	6,844,305	$47.4M	1.4%	+2,000,925
Spruce Street Capital LP	6,391,328	$44.2M	8.7%	+129,214
Adage Capital Partners Gp, L.l.c.	4,763,158	$33.0M	0.0%	No change
Vanguard Capital Management LLC	4,460,210	$30.9M	0.0%	+1,383,640
Jones Hill Capital LP	3,655,075	$25.3M	5.4%	+3,312,323
Orbimed Advisors LLC	3,631,195	$25.1M	0.5%	−1,084,669
State Street Corp	2,517,550	$17.4M	0.0%	+2,160,510
Geode Capital Management, LLC	2,492,573	$17.3M	0.0%	+1,643,890
Millennium Management LLC	2,361,827	$16.3M	0.0%	−1,545,438
Marshall Wace, Llp	2,246,839	$15.5M	0.0%	−2,234,767
Ikarian Capital, LLC	2,148,359	$14.9M	2.4%	−540,000
Driehaus Capital Management LLC	2,132,053	$14.8M	0.1%	No change
Ameriprise Financial Inc	1,937,972	$13.4M	0.0%	+347,026
Eventide Asset Management, LLC	1,858,416	$12.9M	0.2%	+1,016,310
Balyasny Asset Management L.P.	1,520,688	$10.5M	0.0%	+1,268,231
Stempoint Capital LP	1,460,093	$10.1M	1.7%	+265,275
Commodore Capital LP	1,425,000	$9.9M	0.6%	+791,099
Polar Capital Holdings Plc	1,340,428	$9.3M	0.0%	−74,193
Citadel Advisors LLC	1,061,665	$7.3M	0.0%	New
Sio Capital Management, LLC	1,003,562	$6.9M	1.2%	+38,562
Opaleye Management Inc.	935,000	$6.5M	0.6%	No change
Vanguard Portfolio Management LLC	898,198	$6.2M	0.0%	New

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

2 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

Date	Member	Trade	Amount	Vs S&P since	Filing
Dec 12, 2022	Christopher L. Jacobs, House	Sale	$1,001 - $15,000	+98.6%	Report
Nov 8, 2022	Christopher L. Jacobs, House	Buy	$1,001 - $15,000	−148.5%	Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARRELMADA THERAPEUTICS, INC. filings on SEC EDGAR
2
SEC EDGARRELMADA THERAPEUTICS, INC. filings on SEC EDGAR
3
SEC EDGARRELMADA THERAPEUTICS, INC. 10-K for fiscal 2019
4
SEC EDGARRELMADA THERAPEUTICS, INC. 10-K for fiscal 2020
5
SEC EDGARRELMADA THERAPEUTICS, INC. 10-K for fiscal 2021
6
SEC EDGARRELMADA THERAPEUTICS, INC. 10-K for fiscal 2022
7
SEC EDGARRELMADA THERAPEUTICS, INC. 10-K for fiscal 2023
8
SEC EDGARRELMADA THERAPEUTICS, INC. 10-K for fiscal 2024
9
SEC EDGARRELMADA THERAPEUTICS, INC. 10-Q for fiscal 2026
10
SEC EDGARRELMADA THERAPEUTICS, INC. 10-Q for fiscal 2026
11
SEC EDGARSergio Traversa, Chief executive officer
12
SEC EDGAREliseo Oreste Salinas, President
13
SEC EDGARMaged Shenouda, Chief financial officer
14
SEC EDGARChuck Ence, Chief financial officer
15
SEC EDGARDouglas Beck, Chief financial officer
16
SEC EDGARPaul Edward Kelly, Chief operating officer
17
SEC EDGARChuck Ence, Chief operating officer
18
SEC EDGARCedric O'Gorman, Chief Medical Officer
19
SEC EDGARChuck Ence, Chief Compliance Officer
20
SEC EDGAROttavio Vitolo V., Chief Medical Officer
21
SEC EDGARLisa Nolan, Chief Business Officer
22
SEC EDGARFabiana Fedeli, Board member
23
SEC EDGARJohn Glasspool, Board member
24
SEC EDGARNabil Yazgi, Board member
25
SEC EDGARSandesh Seth, Board member
26
SEC EDGARShreeram Agharkar, Board member
27
SEC EDGARCharles J. Casamento, Board member
28
SEC EDGARMaged Shenouda, Board member
29
SEC EDGARPaul Edward Kelly, Board member